Roivant Sciences Ltd. (ROIV)
ROIV · Health Care · 
United States
Roivant Sciences Ltd. (ROIV) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.29%. Anyone who holds an ETF containing Roivant Sciences also has an indirect stake in the company.
Data and Charts: Roivant Sciences
Key Data for Roivant Sciences
Roivant Sciences Stock Price Chart
The Roivant Sciences chart shows daily closing prices and is set to the current year by default. The stock is up 70.1% year to date and up 88.5% over twelve months. The last recorded close on October 30, 2026, was $36.91, at 78% of the 52-week range.
Price series from our database since Sep 3, 2024, 543 daily values.
Roivant Sciences Stock Performance
| Year to date | +70.1% | 1 year | +88.5% |
|---|---|---|---|
| 1 month | +0.9% | 3 months | +8.8% |
| Calendar year 2025 | +83.4% |
Measured in euros, Roivant Sciences is up 78.9% year to date and up 94.9% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Roivant Sciences
What ETF Is Roivant Sciences In?
Roivant Sciences has above-average ETF coverage and is held by 17 of the 104 ETFs we track, which together follow 8 indices. That puts the stock in more ETFs than 78.6% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 0.29% | €2.90 |
| XDWH | MSCI World Health Care | 0.22% | €2.15 |
| SPFS | MSCI World Health Care | 0.21% | €2.09 |
| XDEM | MSCI World Momentum | 0.06% | €0.61 |
| XD9U / XD9D | MSCI USA | 0.03% | €0.29 |
| XDWD / XDWL | MSCI World | 0.02% | €0.21 |
| SWWD | MSCI World | 0.02% | €0.21 |
| SPPW | MSCI World | 0.02% | €0.21 |
| EUNL | MSCI World | 0.02% | €0.20 |
| WIMI | MSCI World IMI | 0.02% | €0.20 |
| SPYY | MSCI ACWI | 0.02% | €0.17 |
| IUSQ | MSCI ACWI | 0.01% | €0.10 |
| SPYI / SPSA | MSCI ACWI IMI | < 0.01% | < €0.05 |
The last column shows how much of €1,000 in one of these funds goes to Roivant Sciences, based on each fund's latest holdings list.
US-listed ETFs holding Roivant Sciences (weight per latest SEC filing): ONEQ 0.05%, VTI 0.02%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Roivant Sciences overlaps with the rest of a portfolio.
What Roivant Sciences Executives and Directors Traded Recently
| Date | Person | Type | Shares | Price |
|---|---|---|---|---|
| Oct 28, 2026 | Venker Eric Officer, President & Immunovant CEO | Sell (plan) | 200,000 | $36.59 |
| Oct 20, 2026 | Venker Eric Officer, President & Immunovant CEO | Sell (plan) | 14,144 | $35.42 |
| Oct 20, 2026 | Venker Eric Officer, President & Immunovant CEO | Sell (plan) | 185,856 | $35.09 |
| Oct 1, 2026 | Epperly Melissa B, Director | Sell (plan) | 900 | $36.57 |
| Oct 1, 2026 | Epperly Melissa B, Director | Sell (plan) | 16,850 | $36.08 |
| Sep 30, 2026 | Venker Eric Officer, President & Immunovant CEO | Sell (plan) | 200,000 | $36.62 |
The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.
“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.
Stocks With ETF Exposure Similar to Roivant Sciences
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Roivant Sciences | – | – | +88.5% | 39.4% | -3,629.2% | -71.6% |
 Revolution Medicines | 17 | – | +225.0% | 56.2% | – | – |
 Insmed Incorporated | 16 | – | -42.0% | 54.9% | -210.5% | +66.7% |
 Medline | 16 | – | – | 43.8% | 4.1% | +11.5% |
 Natera | 16 | – | +114.4% | 46.7% | -9.0% | +35.9% |
| Neurocrine Biosciences | 16 | – | +5.8% | 36.2% | 16.7% | +21.4% |
 United Therapeutics Corporation | 17 | – | +32.0% | 41.2% | 41.9% | +10.6% |
 Royalty Pharma Plc | 17 | – | +81.9% | 23.4% | 32.4% | +5.1% |
 Illumina | 17 | – | +138.3% | 47.5% | 19.6% | -0.7% |
These stocks reach a portfolio through largely the same funds as Roivant Sciences. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Roivant Sciences
Roivant Sciences Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Mar 31, 2026).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Mar 2024 | 0.0 | 4.3 | 13,294.2% |
| FY ended Mar 2025 | 0.0 | -0.2 | -592.0% |
| FY ended Mar 2026 | 0.0 | -0.3 | -3,629.2% |
Technical Analysis: Roivant Sciences
Roivant Sciences Risk Metrics
The close on Oct 30, 2026, was 11.7% below the highest close since Sep 3, 2024. That high was reached on Sep 9, 2026. When the S&P 500 rose or fell 1%, Roivant Sciences moved 1.02% on average in the same direction (past 252 trading days). The correlation of 0.28, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Roivant Sciences.
What Roivant Sciences Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| SOLV | +0.55 | |
| Polkadot | +0.52 | |
| Cosmos | +0.45 | |
| SUSHI | +0.44 | |
| RAY | +0.42 | |
| QKC | +0.41 | |
| ACH | -0.60 | |
| SAPIEN | -0.49 | |
| Stryker Corporation | -0.34 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
